Reviewed by Michael Gill, B. Sc.
25 Oligodendroglioma Clinical Trials Near Me
Top Hospitals for Oligodendroglioma Clinical Trials
Image of Memorial Sloan Kettering Cancer Center in New York.
Memorial Sloan Kettering Cancer Center
New York
5Active Trials
10All Time Trials for Oligodendroglioma
2002First Oligodendroglioma Trial
Image of Washington University School of Medicine in Missouri.
Washington University School of Medicine
Saint Louis
3Active Trials
8All Time Trials for Oligodendroglioma
2004First Oligodendroglioma Trial
Top Cities for Oligodendroglioma Clinical Trials
Image of Chicago in Illinois.
Chicago
6Active Trials
Northwestern UniversityTop Active Site
Top Treatments for Oligodendroglioma Clinical Trials
Treatment Name
Active Oligodendroglioma Clinical Trials
All Time Trials for Oligodendroglioma
First Recorded Oligodendroglioma Trial
dabrafenib
2
2
2017
Craniotomy
1
1
2023
temporally-modulated pulsed radiotherapy (TMPRT)
1
1
2022
Retifanlimab
1
1
2022
Niraparib
1
1
2022
Recently Completed Studies with FDA Approved Treatments for Oligodendroglioma
Treatment
Year
Sponsor
Neural stem cells loaded with an oncolytic adenovirus
2017
Northwestern University

What are Oligodendroglioma Clinical Trials?

Oligodendroglioma is a tumor in the central nervous system (brain or spinal cord). These tumors grow on the frontal or temporal lobes of the brain, or in sporadic cases, in the spinal cord. Oligodendrogliomas consist of tumor cells called oligodendrocytes responsible for protecting the nerves.

Oligodendroglioma can be benign and malignant and usually only spread throughout the central nervous system. There are two types of oligodendrogliomas, depending on the growth rate of the tumor. The benign tumors that grow slowly are considered Grade 2 oligodendroglioma. Malignant tumors that grow and spread quickly are considered Grade 3 anaplastic oligodendroglioma.

Why is Oligodendroglioma Being Studied Through Clinical Trials?

Oligodendroglioma accounts for approximately 5% of all neuroepithelial tumors. Doctors in the United States report around 1200 new Oligodendroglioma patients annually. The disease commonly affects people between the age of 25 to 45, with grade 3 oligodendroglioma presenting almost ten years after the onset of grade 2 tumors.

Recent studies showed that gross tumor resection techniques by chemotherapy for Oligodendroglioma treatment were not effective. Additionally, although it alleviated some symptoms, surgery had a high risk of brain damage.

Hence, doctors turn to Oligodendroglioma clinical trials to find a better method of treating oligodendroglioma that effectively cures the disease without high risk.

What are the Types of Treatment Available for Oligodendroglioma?

One prospective treatment for oligodendroglioma is 60 Gy of postoperative radiationtherapy (XRT) in 30 fractions. However, oligodendroglioma clinical trials are needed to address the efficacy of XRT treatment in different forms of oligodendroglioma.

Additionally, chemotherapy regimens involving vincristine (PVC) and temozolomide (TMZ) showed promising results, further cemented by the Radiation Therapy Oncology Group in a phase 2 study involving pre-irradiation TMZ, which was followed by concurrent TMZ.

Recently, with 12 years of follow-up showing patients with improved survival rates, treatment involving PVC and radiationtherapy (RT) showed promising results in oligodendroglioma clinical trials EORTC26951 and RTOG9402.

What are Some Breakthrough Oligodendroglioma Clinical Trials?

There are currently 66 ongoing oligodendroglioma clinical trials, with three trials in phase 4, ten in phase 3, and 23 in phase 2. Below are some of the most promising oligodendroglioma clinical trials.

NCR03975829: The pediatric long-term follow-up phase 4 study involves 250 participants who will be treated with dabrafenib (DRB436) and trametinib (TMT212). The primary outcome of the study is to assess the safety of treatment of either dabrafenib and trametinib individually or synergistically.

NCT04135807: The phase 1 study is an innovative approach toward tumor resection through a microdevice that uses eight intratumor drugs: TMZ, irinotecan, carboplatin, lomustine, Osimertinib, dinaciclib, and everolimus.

What are the Complications of Oligodendroglioma Clinical Trials?

The oligodendroglioma clinical trials are few, and only a few have gotten to phase 4. This is because many complications in oligodendrogliomas can affect clinical trials. The main complication is the rate at which the tumor grows. Since the rate differs depending on the patients, complications increase when assessing the effectiveness of a trial.

Additionally, most oligodendroglioma clinical trials include strong drugs and radiationtherapy to treat cells surrounding the nervous system, so patients may experience side effects such as:

  • Weakness
  • Nausea and vomiting
  • Balance Problems
  • Loss of hearing or vision

About The Author

Michael Gill preview

Michael Gill - B. Sc.

First Published: October 4th, 2021

Last Reviewed: November 25th, 2022

Michael Gill holds a Bachelors of Science in Integrated Science and Mathematics from McMaster University. During his degree he devoted considerable time modeling the pharmacodynamics of promising drug candidates. Since then, he has leveraged this knowledge of the investigational new drug ecosystem to help his father navigate clinical trials for multiple myeloma, an experience which prompted him to co-found Power Life Sciences: a company that helps patients access randomized controlled trials.

References1 Shahid S, Kushner BH, Modak S, Basu EM, Rubin EM, Gundem G, Papaemmanuil E, Roberts SS. Association of BRAF V600E mutations with vasoactive intestinal peptide syndrome in MYCN-amplified neuroblastoma. Pediatr Blood Cancer. 2021 Oct;68(10):e29265. doi: 10.1002/pbc.29265. Epub 2021 Jul 31. https://pubmed.ncbi.nlm.nih.gov/343315152 Blyth BJ, Farhavar A, Gee C, Hawthorn B, He H, Nayak A, Stöcklein V, Bazarian JJ. Validation of serum markers for blood-brain barrier disruption in traumatic brain injury. J Neurotrauma. 2009 Sep;26(9):1497-1507. doi: 10.1089/neu.2008-0738. https://pubmed.ncbi.nlm.nih.gov/192578033 Liau LM, Prins RM, Kiertscher SM, Odesa SK, Kremen TJ, Giovannone AJ, Lin JW, Chute DJ, Mischel PS, Cloughesy TF, Roth MD. Dendritic cell vaccination in glioblastoma patients induces systemic and intracranial T-cell responses modulated by the local central nervous system tumor microenvironment. Clin Cancer Res. 2005 Aug 1;11(15):5515-25. https://pubmed.ncbi.nlm.nih.gov/160618684 Liau LM, Black KL, Prins RM, Sykes SN, DiPatre PL, Cloughesy TF, Becker DP, Bronstein JM. Treatment of intracranial gliomas with bone marrow-derived dendritic cells pulsed with tumor antigens. J Neurosurg. 1999 Jun;90(6):1115-24. https://pubmed.ncbi.nlm.nih.gov/103502605 Liau LM, Prins RM, Kiertscher SM, Odesa SK, Kremen TJ, Giovannone AJ, Lin JW, Chute DJ, Mischel PS, Cloughesy TF, Roth MD. Dendritic cell vaccination in glioblastoma patients induces systemic and intracranial T-cell responses modulated by the local central nervous system tumor microenvironment. Clin Cancer Res. 2005 Aug 1;11(15):5515-25. https://pubmed.ncbi.nlm.nih.gov/160618686 Chiocca EA, Nakashima H, Kasai K, Fernandez SA, Oglesbee M. Preclinical Toxicology of rQNestin34.5v.2: An Oncolytic Herpes Virus with Transcriptional Regulation of the ICP34.5 Neurovirulence Gene. Mol Ther Methods Clin Dev. 2020 Mar 30;17:871-893. doi: 10.1016/j.omtm.2020.03.028. eCollection 2020 Jun 12. https://pubmed.ncbi.nlm.nih.gov/323736497 Holodny AI, Nusbaum AO, Festa S, Pronin IN, Lee HJ, Kalnin AJ. Correlation between the degree of contrast enhancement and the volume of peritumoral edema in meningiomas and malignant gliomas. Neuroradiology. 1999 Nov;41(11):820-5. https://pubmed.ncbi.nlm.nih.gov/106028548 Gong W, Wang Z, Liu N, Lin W, Wang X, Xu D, Liu H, Zeng C, Xie X, Mei X, Lü W. Improving efficiency of adriamycin crossing blood brain barrier by combination of thermosensitive liposomes and hyperthermia. Biol Pharm Bull. 2011;34(7):1058-64. https://pubmed.ncbi.nlm.nih.gov/217200139 Dunn GP, Dunn IF, Curry WT. Focus on TILs: Prognostic significance of tumor infiltrating lymphocytes in human glioma. Cancer Immun. 2007 Aug 13;7:12. Review. https://pubmed.ncbi.nlm.nih.gov/1769171410 Thomas AA, Abrey LE, Terziev R, Raizer J, Martinez NL, Forsyth P, Paleologos N, Matasar M, Sauter CS, Moskowitz C, Nimer SD, DeAngelis LM, Kaley T, Grimm S, Louis DN, Cairncross JG, Panageas KS, Briggs S, Faivre G, Mohile NA, Mehta J, Jonsson P, Chakravarty D, Gao J, Schultz N, Brennan CW, Huse JT, Omuro A. Multicenter phase II study of temozolomide and myeloablative chemotherapy with autologous stem cell transplant for newly diagnosed anaplastic oligodendroglioma. Neuro Oncol. 2017 Oct 1;19(10):1380-1390. doi: 10.1093/neuonc/nox086. https://pubmed.ncbi.nlm.nih.gov/28472509